Promoting sun protection among student athletes
11 October 2017Education directed to student athletes, athletic trainers and coaches can improve sun-protective practices in student athletes, according to authors of this US study.
Education directed to student athletes, athletic trainers and coaches can improve sun-protective practices in student athletes, according to authors of this US study.
Improved awareness of the atypical presentations of melanoma is required to reduce mortality, according to the Australian working group currently revising and updating the 2008 guidelines. Of particular importance is improved recognition of nodular, desmoplastic and acral lentiginous subtypes, with particular awareness of hypomelanotic and amelanotic lesions.
Results of this Danish study showed no difference in overall survival between patients with melanoma of unknown primary and patients with a known primary with stage III or IV disease.
Results of this study found that in patients with malignant melanoma involving the limbs, the proximity of the primary skin tumour to the lymph node basin may have influence on sentinel lymph node positivity.
Study results confirm recent observation that β-blockers protect patients with thick cutaneous melanoma from disease recurrence, according to the authors.
Results of this study suggest that the increased melanoma incidence and mortality among pilots and airline cabin crews may not be related to in-flight UV radiation exposure, according to its authors.
Study findings support the hypothesis that the pathogenesis of uveal melanoma is more dependent on UV radiation than previously thought.
The need for increased awareness of melanoma-related limb lymphoedema is highlighted by study findings that it occurs in 25% of melanoma patients and has a significant negative impact on health-related quality of life.
Patients with a skin lesion suspected to be melanoma had to wait an average of 114 days from their first appointment to treatment, according to an audit carried out at Waikato Hospital.
Patients whose tumours had NRAS mutations had better response to immunotherapy and better outcomes than patients whose tumours had other genetic subtypes, according to the authors of this study. They conclude that immune therapies - especially immune checkpoint inhibitors - may be particularly effective as treatment options for NRAS-mutant melanoma.